##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 Form 10-K/A
 (Amendment No. 1)
 (Mark One)
 o
    
    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the fiscal year ended
 or
 þ
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from December 31, 2008 to March 31, 2009
 Commission file number:000-52530
 Omni Bio Pharmaceutical, Inc.
  Colorado
    
    20-8097969(State or Other Jurisdiction of 
Incorporation or Organization)
    
    (I.R.S. Employer
Identification No.)
 5350 South Roslyn, Suite 430, Greenwood Village, CO 80111
 303-867-3415
   Common Stock Par Value $0.001
 o þ
 o þ
 þ o
 o o
 þ
  Large accelerated filer o
    
    Accelerated filer o
    
    Non-accelerated filer o
(Do not check if a smaller reporting company)
    
    Smaller reporting company þ
 o þ




---



##### 



TABLE OF CONTENTS
 PART IIItem 8. Financial Statements and Supplementary Data
    
    
    4PART IVItem 15. Exhibits and Financial Statement Schedules
    
    
    4SIGNATURES
    
    
    7Exhibit 10.18Exhibit 31.1Exhibit 31.2Exhibit 32.1Exhibit 32.2
   2




---



##### Table of Contents



EXPLANATORY NOTE
    3




---



##### Table of Contents



ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
   
 PART IV
 
 ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
  REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
     HEIN & ASSOCIATES LLP
 
  4




---



##### Table of Contents



EXHIBIT #
    
    DESCRIPTION2.1
    
    
    Agreement of Merger and Plan of Reorganization dated November 17,
2008 (incorporated by reference to Exhibit 10.3 to the Registrants
Form 8-K filed on November 21, 2008)2.2
    
    
    Agreement to Amend and Extend Agreement of Merger and Plan of
Reorganization dated February 11, 2009 (incorporated by reference to
Exhibit 10.4 to the Registrants Form 8-K filed on February 18, 2009)2.3
    
    
    Second Agreement to Amend and Extend Agreement of Merger and Plan of
Reorganization dated March 11, 2009 (incorporated by reference to
Exhibit 10.5 to the Registrants Form 8-K filed on March 13, 2009)2.4
    
    
    Third Agreement to Amend Agreement of Merger and Plan of
Reorganization dated March 30, 2009 (incorporated by reference to
Exhibit 2.4 to the Registrants Form 8-K filed on April 6, 2009)2.5
    
    
    Agreement and Plan of Merger between Maxcure Pharmaceutical, Inc. and
Apro Bio Pharmaceutical Corporation dated March 18, 2008
(incorporated by reference to Exhibit 2.5 to the Registrants Annual
Report on Form 10-K filed on June 29, 2009)3.1
    
    
    Articles of Incorporation (incorporated by reference to Exhibit 3.1
to the Registrants Registration Statement on Form SB-2 filed on
March 2, 2007)3.2
    
    
    Bylaws (incorporated by reference to Exhibit 3.2 to the Registrants
Registration Statement on Form SB-2 filed on March 2, 2007)3.3
    
    
    Articles of Amendment for Across America Financial Services, Inc.
including Amendment to Articles of Incorporation of Across America
Financial Services, Inc. (incorporated by reference to Exhibit 3.3 to
the Registrants Form 8-K filed on June 2, 2009)4.1
    
    
    Warrant dated January 12, 2007 for Safe Harbor Business Development
Company (incorporated by reference to Exhibit 10.1 to the
Registrants Registration Statement on Form SB-2 filed on March 2,
2007)10.1
    
    
    Promissory Note dated January 2, 2007 with West Mountain Prime, LLC
(incorporated by reference to Exhibit 10.1 to the Registrants
Registration Statement on Form SB-2 filed on March 2, 2007)10.2
    
    
    Promissory Note dated October 16, 2008 with West Mountain Prime, LLC
(incorporated by reference to the Registrants Form 8-K filed on
November 7, 2008)10.3
    
    
    Exclusive License Agreement with the University of Colorado dated
May 15, 2006 (incorporated by reference to Exhibit 10.4 to the
Registrants Form 8-K filed on April 6, 2009)10.4
    
    
    Subscription Agreement with University License Equity Holdings, Inc.
dated May 15, 2006, as amended (incorporated by reference to Exhibit
10.5 to the Registrants Form 8-K filed on April 6, 2009)10.5
    
    
    Sponsored Research Agreement with the University of Colorado dated
May 15, 2006, as amended (incorporated by reference to Exhibit 10.6
to the Registrants Form 8-K filed on April 6, 2009)10.6
    
    
    Services Agreement with Colorado State University System dated June
18, 2007 (incorporated by reference to Exhibit 10.7 to the
Registrants Form 8-K filed on April 6, 2009)
  5




---



##### Table of Contents



EXHIBIT #
    
    DESCRIPTION10.7
    
    
    Exclusive License Agreement with the University of Colorado dated
March 31, 2008, as amended (incorporated by reference to Exhibit
10.8 to the Registrants Form 8-K filed on April 6, 2009)10.8
    
    
    Exclusive License Agreement with the University of Colorado dated
November 12, 2008 (incorporated by reference to Exhibit 10.9 to the
Registrants Form 8-K filed on April 6, 2009)10.9
    
    
    Settlement Agreement with David Olson (incorporated by reference to
Exhibit 10.10 to the Registrants Form 8-K filed on April 6, 2009)10.10
    
    
    Settlement Agreement with David Floor (incorporated by reference to
Exhibit 10.11 to the Registrants Form 8-K filed on April 6, 2009)10.11
    
    
    Form of Advisor Warrant dated March 31, 2009 (incorporated by
reference to Exhibit 10.11 to the Registrants Annual Report on Form
10-K filed on June 29, 2009)10.12
    
    
    Subscription Agreement and Letter of Investment (incorporated by
reference to Exhibit 10.12 to the Registrants Annual Report on Form
10-K filed on June 29, 2009)10.13
    
    
    Form of Investor Warrant exercisable at $0.25 per share dated March
31, 2009 (incorporated by reference to Exhibit 10.13 to the
Registrants Annual Report on Form 10-K filed on June 29, 2009)10.14
    
    
    Form of Investor Warrant exercisable at $0.50 per share dated March
31, 2009 (incorporated by reference to Exhibit 10.14 to the
Registrants Annual Report on Form 10-K filed on June 29, 2009)10.15
    
    
    Form of Investor Warrant exercisable at $1.00 per share dated March
31, 2009 (incorporated by reference to Exhibit 10.15 to the
Registrants Annual Report on Form 10-K filed on June 29, 2009)10.16
    
    
    Form of Two-Year Subscription and Lock-up Agreement (incorporated by
reference to Exhibit 10.16 to the Registrants Annual Report on Form
10-K filed on June 29, 2009)10.17
    
    
    Form of Three-Year Subscription and Lock-up Agreement (incorporated
by reference to Exhibit 10.17 to the Registrants Annual Report on
Form 10-K filed on June 29, 2009)10.18
    
    
    Warrant dated April 7, 2009 issued to Charles A. Dinarello #10.19
    
    
    Warrant dated December 16, 2009 issued to Charles A. Dinarello
(incorporated by reference to Exhibit 10.1 to the Registrants
Current Report on Form 8-K filed on December 22, 2009)21
    
    
    Subsidiaries of the Registrant (incorporated by reference to Exhibit
21 to the Registrants Annual Report on Form 10-K filed on June 29,
2009)31.1
    
    
    Certification of Acting Chief Executive Officer Pursuant to Rule
13a-14(a) under the Securities Exchange Act of 1934 #31.2
    
    
    Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)
under the Securities Exchange Act of 1934 #32.1
    
    
    Certification of Acting Chief Executive Officer Pursuant to Section
1350 of Chapter 63 of Title 18 of the United States Code #32.2
    
    
    Certification of Chief Financial Officer Pursuant to Section 1350 of
Chapter 63 of Title 18 of the United States Code #
 
 #
    
    Filed herewith  6




---



##### Table of Contents



SIGNATURES
  OMNI BIO PHARMACEUTICAL, INC.November 8, 2010
    By:
    /s/   Robert C. OgdenRobert C. OgdenChief Financial Officer
(Principal Financial and Accounting Officer)  7